Geron (GERN) Competitors $1.42 +0.03 (+1.79%) Closing price 07/3/2025 03:23 PM EasternExtended Trading$1.42 0.00 (0.00%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock GERN vs. ALKS, LGND, BCRX, FOLD, CLDX, INVA, DVAX, MNKD, OPK, and NVAXShould you be buying Geron stock or one of its competitors? The main competitors of Geron include Alkermes (ALKS), Ligand Pharmaceuticals (LGND), BioCryst Pharmaceuticals (BCRX), Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), Innoviva (INVA), Dynavax Technologies (DVAX), MannKind (MNKD), OPKO Health (OPK), and Novavax (NVAX). These companies are all part of the "biotechnology" industry. Geron vs. Its Competitors Alkermes Ligand Pharmaceuticals BioCryst Pharmaceuticals Amicus Therapeutics Celldex Therapeutics Innoviva Dynavax Technologies MannKind OPKO Health Novavax Geron (NASDAQ:GERN) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk. Do analysts recommend GERN or ALKS? Geron presently has a consensus price target of $5.06, indicating a potential upside of 255.26%. Alkermes has a consensus price target of $40.00, indicating a potential upside of 39.13%. Given Geron's higher possible upside, equities analysts plainly believe Geron is more favorable than Alkermes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Geron 0 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.78Alkermes 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.83 Do institutionals & insiders have more ownership in GERN or ALKS? 73.7% of Geron shares are owned by institutional investors. Comparatively, 95.2% of Alkermes shares are owned by institutional investors. 7.4% of Geron shares are owned by company insiders. Comparatively, 4.4% of Alkermes shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has stronger earnings and valuation, GERN or ALKS? Alkermes has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGeron$76.99M11.79-$174.57M-$0.21-6.79Alkermes$1.56B3.04$367.07M$2.0913.76 Is GERN or ALKS more profitable? Alkermes has a net margin of 23.30% compared to Geron's net margin of -119.54%. Alkermes' return on equity of 27.52% beat Geron's return on equity.Company Net Margins Return on Equity Return on Assets Geron-119.54% -47.86% -26.78% Alkermes 23.30%27.52%17.98% Does the media refer more to GERN or ALKS? In the previous week, Alkermes had 10 more articles in the media than Geron. MarketBeat recorded 10 mentions for Alkermes and 0 mentions for Geron. Alkermes' average media sentiment score of 1.10 beat Geron's score of 0.00 indicating that Alkermes is being referred to more favorably in the news media. Company Overall Sentiment Geron Neutral Alkermes Positive Which has more risk & volatility, GERN or ALKS? Geron has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500. SummaryAlkermes beats Geron on 12 of the 16 factors compared between the two stocks. Get Geron News Delivered to You Automatically Sign up to receive the latest news and ratings for GERN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GERN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GERN vs. The Competition Export to ExcelMetricGeronMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$910.79M$2.92B$5.56B$9.05BDividend YieldN/A2.44%5.24%3.99%P/E Ratio-6.7921.5627.6520.23Price / Sales11.79283.26419.56119.26Price / CashN/A41.7026.2128.59Price / Book3.107.538.035.65Net Income-$174.57M-$55.14M$3.18B$249.15M7 Day Performance-4.36%4.61%2.93%3.28%1 Month Performance-10.94%0.90%1.72%3.95%1 Year Performance-68.54%5.40%34.39%20.98% Geron Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GERNGeron2.8427 of 5 stars$1.43+1.8%$5.06+255.3%-68.5%$910.79M$76.99M-6.7970ALKSAlkermes4.9344 of 5 stars$28.60-0.7%$40.00+39.9%+18.4%$4.72B$1.56B13.681,800Positive NewsAnalyst RevisionLGNDLigand Pharmaceuticals4.8114 of 5 stars$113.68-0.4%$146.14+28.6%+35.6%$2.19B$167.13M-15.9780News CoverageBCRXBioCryst Pharmaceuticals4.4641 of 5 stars$8.96-4.3%$16.89+88.5%+37.2%$1.87B$450.71M-34.46530Analyst ForecastAnalyst RevisionFOLDAmicus Therapeutics3.7015 of 5 stars$5.73-3.4%$16.22+183.1%-38.6%$1.76B$528.29M-63.66480CLDXCelldex Therapeutics3.066 of 5 stars$20.35+0.3%$50.11+146.2%-38.1%$1.35B$7.02M-7.54150Positive NewsINVAInnoviva3.8918 of 5 stars$20.09+0.7%$55.00+173.8%+17.4%$1.26B$358.71M-19.89100Positive NewsDVAXDynavax Technologies4.3933 of 5 stars$9.92+0.1%$24.00+141.9%-8.6%$1.19B$277.25M-19.08350MNKDMannKind2.5262 of 5 stars$3.74-0.5%$10.33+176.3%-29.7%$1.14B$297.60M37.40400OPKOPKO Health4.443 of 5 stars$1.32flat$2.75+108.3%+6.7%$1.05B$713.10M-18.852,997Positive NewsNVAXNovavax4.4897 of 5 stars$6.30-1.1%$17.00+169.8%-42.9%$1.02B$682.16M2.381,990 Related Companies and Tools Related Companies ALKS Competitors LGND Competitors BCRX Competitors FOLD Competitors CLDX Competitors INVA Competitors DVAX Competitors MNKD Competitors OPK Competitors NVAX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GERN) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Geron Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Geron With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GERN Stock Alerts